Journal
CLINICAL ONCOLOGY
Volume 27, Issue 5, Pages 307-315Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2015.01.032
Keywords
Ablative therapy; liver; metastases; SABR; SBRT; stereotactic
Categories
Funding
- National Health Service
- Cridlan Trust
- MRC grant [MC_PC_12001/2]
- Medical Research Council [MC_PC_12001/2] Funding Source: researchfish
- MRC [MC_PC_12001/2] Funding Source: UKRI
Ask authors/readers for more resources
The role for local ablative therapies in the management paradigm of oligometastatic liver disease is increasing. The evidence base supporting the use of stereotactic body radiotherapy for liver metastases has expanded rapidly over the past decade, showing high rates of local control with low associated toxicity. This review summarises the evidence base to date, discussing optimal patient selection, challenges involved with treatment delivery and optimal dose and fractionation. The reported toxicity associated with liver stereotactic body radiotherapy is presented, together with possible pitfalls in interpreting the response to treatment using standard imaging modalities. Finally, potential avenues for future research in this area are highlighted. (C) 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available